Breast Cancer Clinical Trial
Official title:
The Efficacy of Reduced-exertion High-intensity Interval Training for Improving Health and Well-being in Newly Diagnosed Female Breast Cancer Patients
Treatment of cancer patients should not only involve removing the cancer, but should also focus on maintaining good health and well-being and quality of life. This can be done by offering patients suitable rehabilitation programmes. Previous research has shown that such programmes need to involve exercise alongside other components, such as psychological support. To date most studies have looked at the positive effects of moderate-intensity exercise such as brisk walking, but this type of exercise is time-consuming and often not done by many patients. Shorter-duration exercise routines consisting of repeated short sprints have been found to improve general health just as well, but one of the most time-efficient routines (termed 'reduced-exertion high-intensity interval training', or 'REHIT') has not been studied in cancer patients. REHIT involves 3 exercise sessions per week, each only 10 minutes long. This makes it an ideal routine to combine with other components of a cancer rehabilitation programme. The present study will determine whether REHIT can improve important markers of health and well-being in newly diagnosed breast cancer patients. To achieve this the investigators will recruit up to 30 patients and divide them into a group who will do REHIT before and for up to 6 weeks after their cancer surgery, and a control group who will receive standard care. Markers of health and well-being will be measured at the start of the study, ~1 week after surgery, and ~7 weeks after surgery. Any changes will be compared between the exercise group and the control group. If beneficial effects are found with the REHIT intervention then this could be more widely implemented as part of cancer treatment. This study is funded by Nuffield Health and will be performed in Oxford, UK.
This study involves a randomised controlled trial: study participants will be randomly
allocated to either a group who will receive the care that they would normally have received
if they would not have been in the study (control group), and a group who will receive the
same standard care but will also be asked to follow a novel supervised exercise routine three
times per week before their surgery and for up to 6 weeks after surgery, as well as some
psychological support.
Up to 30 newly-diagnosed female breast cancer patients will be recruited. Following written
informed consent, participants will be invited for a baseline testing session. This will
involve a fasting blood sample (ideally at a time when the patient's medical team would take
a blood sample anyway). The investigators will analyse this sample for a number of markers of
health, such as blood sugar and fat levels, and markers of inflammation. The investigators
will measure the patients' height with a stadiometer, and weight and body fat percentage
using a special set of scales. The investigators will ask patients to complete several
questionnaires that ask questions about their current well-being. Finally the investigators
will measure the patients' handgrip strength as well as their fitness levels. The grip
strength test involves squeezing a handheld device as hard as possible for a few seconds. The
fitness test involves cycling on a stationary bike with a gradually increasing resistance
until the patient cannot continue any longer because of fatigue. In this test the
investigators will ask patients to breathe through a tube to determine the maximal amount of
oxygen they can take up during exercise. This measure (termed VO2max) is one of the best
health markers that can be measured: it is the best predictor of future risk of chronic
disease or premature death. All testing sessions will be performed at the Manor Hospital in
Oxford (unless the equipment required for the analysis of VO2max is not available for a
period of time, in which case patients will be invited to attend Oxford Brookes campus for
the fitness test; this is a 4-minute drive from the Manor Hospital).
Ideally, the blood samples will be taken in a fasted state (i.e. in the morning without
having had breakfast), whereas the fitness test will be done after the patient has last had
some food. The investigators will therefore provide the participants with a light snack after
the blood sample has been taken. In case a patient cannot attend the hospital in the morning
in a fasted state then they will arrange the session at a later time of day and the patient
will not be required to be fasted (leading to loss of some of the secondary outcome measures
which require a fasted state).
After the baseline testing has been completed the investigators will tell patients whether
they will be in the control group or in the exercise group. Patients in the control group
will receive their standard care as if they would not have participated in the study. The
research team will not interact with these patients until the second testing session.
Patients in the exercise group will be invited to perform 3 fully supervised exercise
sessions per week at the Manor Hospital. These exercise sessions will involve 10 minutes of
cycling at a low intensity, but with 2 brief cycle sprints after 2 and 6 minutes. The sprints
will last 10 seconds in the first week of training, 15 seconds in the second week, and 20
seconds from week 3 onward. Training sessions will be stopped at least 2 days prior to the
scheduled surgery date.
Surgery will interrupt the exercise programme. Between 7 and 10 days post-surgery, or when
the consultant breast surgeon deems appropriate, all patients will undergo post-surgery
testing. Testing procedures will be identical as those for baseline testing.
Following post-surgery testing, patients in the exercise group will resume the exercise
programme. The duration of the sprints will restart at 10 seconds in the first week, 15
seconds in the second week, and 20 seconds in the remaining weeks. The exercise routine will
be continued until follow-up treatment or for a period of up to 6 weeks. Before or after one
of the 3 weekly exercise sessions, patients will receive a 30/40-minute face-to-face session
with a psychologist. The aim of these sessions will be to reduce emotional distress, improve
mental adjustment, promote a sense of personal control over current experience, develop
effective coping strategies for dealing with cancer-related difficulties, and open expression
of emotion. If patients cannot attend psychological support sessions then they will be
offered the opportunity to catch up through a session over the phone.
Approximately 3 days following the final training session patients will undergo end-of-trial
testing, identical to the previous two testing sessions. Patients in the control group will
undergo this testing session at a time-point equivalent to that of patients in the exercise
group.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |